Tech Company Financing Transactions
FLX Bio Funding Round
On 4/30/2016, FLX Bio landed $50 million in Series B funding from Celgene, Kleiner Perkins Caufield & Byers and The Column Group.
Transaction Overview
Company Name
Announced On
4/30/2016
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series B
Proceeds Purpose
The funds will be used to support further discovery and development of its pipeline of novel immuno-oncology compounds and to advance development of the company's Phase 1 clinical compound, FLX925, a selective inhibitor of FLT3 and CDK4/6, in a proof-of-concept study in patients with acute myeloid leukemia.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
561 Eccles Ave.
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Founded in 2015, FLX Bio Inc. is a privately-held biopharmaceutical company focused on the discovery, development and commercialization of novel immuno-oncology agents.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Brian Wong
Chief Medical Officer
William Ho
Chief Operating Officer
Rekha Hemrajani
Vice President
Dirk Brockstedt
Vice President
Paul Kassner
Vice President
David Wustrow
Browse more venture capital transactions:
Prev: 4/30/2016: Sienna Biopharmaceuticals venture capital transaction
Next: 4/30/2016: Sirnaomics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs